Skip to main content
Premium Trial:

Request an Annual Quote

Tripos Announces Deals with GSK, Schering-Plough, Others

NEW YORK, Jan. 25 (GenomeWeb News) - Tripos today announced a series of new and extended collaborations with five US and European pharmaceutical and life sciences companies.


The St. Louis-based company said it will work with GlaxoSmithKline, Schering-Plough, Genzyme, Cenes, and Gemin X Biotechnologies to deliver customized chemistry services.


Specifically, Tripos said the activities with its partners will include medicinal chemistry programs, the development of Tripos' new compounds for its small molecule screening collection, and the creation of follow-up libraries based on hits from LeadQuest.


Financial details were not disclosed.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.